Novartis has a secured an important win, at least for now, in a case pertaining to the alleged infringement of the patent for its blockbuster heart failure therapy Entresto (sacubitril/valsartan) in India.
In a recent injunction, the Delhi High Court restrained the local companies Natco Pharma, Torrent Pharmaceuticals, Eris LifeSciences...






